Monopar Therapeutics (MNPR) Cash from Investing Activities (2022 - 2025)

Monopar Therapeutics has reported Cash from Investing Activities for 4 years, with the latest figure at -$62.2 million in Q4 2025.

• Quarterly Cash from Investing Activities fell 333.72% year-over-year to -$62.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$63.5 million (down 342.54% YoY) and the FY2025 annual result came in at -$63.5 million, down 342.54% from the prior year.
• Cash from Investing Activities retreated to -$62.2 million in Q4 2025 per MNPR's latest filing, from -$2.1 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $3.0 million in Q4 2023 and troughed at -$62.2 million in Q4 2025.
• A 4-year average of -$6.0 million and a median of -$325828.0 in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities tumbled 582.7% in 2024, then surged 49100.99% in 2025.
• Over 4 years, Cash from Investing Activities stood at -$4.9 million in 2022, then surged by 160.39% to $3.0 million in 2023, then sank by 582.7% to -$14.3 million in 2024, then tumbled by 333.72% to -$62.2 million in 2025.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$62.2 million, -$2.1 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.